Brief Title
An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors
Official Title
An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors
Brief Summary
Patients are asked to participate in this study if they have been diagnosed with a thoracic carcinoma which includes lung cancer and have a gene mutation (alteration in the body's genetic instructions) and after undergoing treatment the cancer has come back, progressed, or shown a partial response on standard treatment.
Detailed Description
In order to improve the treatment outcome for thoracic carcinomas after they become resistant to targeted therapy, the investigator is using tumor biopsies at the time of recurrence for genomic analysis to identify novel somatic changes in critical genes and gene pathways that can potentially be targeted with therapy. The study team is also creating patient-derived xenografts to test drug efficacy and optimize personalized therapy for each patient.
Study Type
Observational
Primary Outcome
Identify the number of molecular changes in the recurrent tumor through molecular analysis with gene panels.
Secondary Outcome
Recording turn-around-time
Condition
Adenocarcinoma of Lung
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Estimated Enrollment
15
Start Date
October 2014
Completion Date
December 2019
Primary Completion Date
October 2018
Eligibility Criteria
Inclusion Criteria: - 18 years or older - Thoracic carcinoma tumors are positive for any targetable genetic alterations - Have shown partial or no response, progression or recurrence while on or after gene targeted therapy by CT/PET scan - Tumor is accessible for biopsy or surgery - Expected life is 6 months or longer. Exclusion Criteria: - < 18 years - Not able to communicate in English
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
Jin Jen, MD, PhD, ,
Location Countries
United States
Location Countries
United States
Administrative Informations
NCT ID
NCT02616211
Organization ID
14-002084
Responsible Party
Principal Investigator
Study Sponsor
Mayo Clinic
Collaborators
National Foundation for Cancer Research
Study Sponsor
Jin Jen, MD, PhD, Principal Investigator, Mayo Clinic
Verification Date
October 2020